Loading stock data…
ATOS
$5.33-0.04 (-0.74%)
Market ClosedLast close May 1
Atossa Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Atossa Therapeutics, Inc. in the Healthcare sector is trading at $5.33. The stock is currently near its 52-week low of $3.76, remaining 45.6% below its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why ATOS maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.33
Potential Upside
5%
Whystock Fair Value$5.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$23.00+331.5%
Range$20.00 – $25.00
Fundamentals
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candida...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$51.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-75.80%
Volume
Today's trading volume
34,680
Recent News
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Strong Sell Stocks for Oct. 22
ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity
Atossa Therapeutics, Inc. (NASDAQ:ATOS) is among the best growth stocks to invest in for the next 5 years. Ascendiant Capital analysts slightly increased the price target for Atossa Therapeutics, Inc. (NASDAQ:ATOS) to $7.50, up from $7.25, with an unchanged Buy rating. This potential surge of 837% from current levels reinforces the company’s attractive valuation. In […]
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.